Clinical trials
Phase 1 Huntington Disease trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
45 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 13 |
| 2011 | 4 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 30 |
| Unknown status | 6 |
| Recruiting | 3 |
| Terminated | 3 |
| Withdrawn | 1 |
| Not yet recruiting | 1 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pfizer | 9 |
| CHDI Foundation, Inc. | 4 |
| Luye Pharma Group Ltd. | 4 |
| Siena Biotech S.p.A. | 3 |
| ExoRNA Bioscience | 2 |
| GlaxoSmithKline | 2 |
| Hoffmann-La Roche | 2 |
| Institute for Neurodegenerative Disorders | 2 |
| University of Rochester | 2 |
| Alnylam Pharmaceuticals | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Huntington Disease | 45 |
| Alzheimer Disease | 10 |
| Chorea | 4 |
| Mental Disorders | 4 |
| Movement Disorders | 3 |
| Neurodegenerative Diseases | 3 |
| Tardive Dyskinesia | 3 |
| Basal Ganglia Diseases | 2 |
| Brain Diseases | 2 |
| Central Nervous System Diseases | 2 |
Trials
Showing 26 to 45 of 45. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.